Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotechnology Value Fund, L.P. -- Ignore unavailable to you. Want to Upgrade?

To: scaram(o)uche who wrote (437)	2/25/1999 2:44:00 PM
From: mike head	Read Replies (1) \| Respond to of 4974

Kinda complicated, maybe, but what the Hell... I'll plug in CTRX (thinking of Tex Dude). mch

To: scaram(o)uche who wrote (437)	3/2/1999 4:09:00 PM
From: Jorgen Jensen	Read Replies (2) \| Respond to of 4974

Submission for daily contest: Tuesday March 2, 10:25 am Eastern Time SOURCE: Medtronic, Inc. Medtronic and Cognetix to Collaborate on Revolutionary New Approach for the Treatment of Epilepsy Treatment May Reduce Seizures Without Sedation and Functional Impairment MINNEAPOLIS and SALT LAKE CITY, Utah, March 2 /PRNewswire/ -- Medtronic, Inc. (NYSE: MDT - news), and Cognetix, Inc., announced today that they will collaborate to develop and commercialize a revolutionary new approach for the treatment of severe epilepsy. This new treatment is intended to reduce seizure activity without the sedation and functional impairment common with many current epilepsy treatments. Terms of the agreement were not disclosed. It is estimated that more than 2.5 million people in the United States suffer from some form of epilepsy. Approximately 20 percent of these individuals do not receive adequate control of seizures with currently- available medications, leaving surgical intervention as the only therapeutic option. In this collaboration, the Medtronic SynchroMed® Infusion System will be used to deliver a compound called Conantokin G (Con G) from Cognetix directly into the brains of patients with epilepsy. Derived from Conus sea snail venoms, Con G is a conopeptide that may control convulsions. In preclinical studies, Con G reduced seizure activity without the sedation and functional impairment characteristic of many current epilepsy treatments. Con G's efficacy is based on its unique ability to target only those brain receptors that control seizures.